Dados do Trabalho

Título

Dupilumab treatment normalizes skin barrier function in children aged 6 to 11 years with moderate-to-severe atopic dermatitis

Resumo

Introduction: This analysis reports the effect of dupilumab (DPL) treatment in patients aged 6–11 years with moderate-to-severe atopic dermatitis (AD) on skin barrier function, clinician- and patient-reported outcomes.
Methods: In the PELISTAD open-label study (NCT04718870), patients aged 6–11 years with moderate-to-severe AD were treated with DPL for 16 weeks (300 mg every 4 weeks: ≥15 kg to <30 kg; 200 mg every 2 weeks: ≥30 kg to <60 kg) and matched with healthy volunteers. Transepidermal water loss (TEWL) was assessed longitudinally after skin tape strippings (STS) from lesional and nonlesional skin of AD patients treated with DPL and from healthy skin. Eczema Area and Severity Index (EASI) and Children’s Dermatology Life Quality Index (CDLQI) were assessed during the same periods.
Results: The median TEWL after 5 STS significantly decreased after 16 weeks of DPL treatment in the lesional and nonlesional skin of patients with AD (P<0.0001 for lesional skin, and P<0.05 for nonlesional skin, vs Day 1). At Week 16, median TEWL after 5 STS in nonlesional skin reached levels comparable to those of healthy skin (P=0.266). Mean (standard deviation [SD]) EASI went from 37.7±11.1 at Day 1 to 10.7±10.3 at Week 16 and mean (SD) CDLQI from 18.4±7.3 to 4.5±2.8 between Day 1 and Week 16. Out of 23, 21 patients reported treatment-emergent adverse events. None were serious, severe, or led to treatment discontinuation.
Conclusion: DPL treatment normalizes skin barrier function, and improves clinician- and patient-reported outcomes in patients aged 6–11 years with moderate-to-severe AD.